Global and United States Alpha 1 Antitrypsin Deficiency Treatment Market Report & Forecast 2022-2028
SKU ID : QYR-20988048 | Publishing Date : 27-May-2022 | No. of pages : 99
Detailed TOC of Global and United States Alpha 1 Antitrypsin Deficiency Treatment Market Report & Forecast 2022-2028
1 Study Coverage1.1 Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Introduction
1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Outlook 2017 VS 2022 VS 2028
1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028
1.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028
1.3 Alpha 1 Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Alpha 1 Antitrypsin Deficiency Treatment in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Alpha 1 Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
1.4.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
1.4.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
1.4.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
1.4.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Alpha 1 Antitrypsin Deficiency Treatment by Indication
2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Segment by Indication
2.1.1 Augmentation Therapy
2.1.2 Cystic Fibrosis(CF)
2.1.3 Non-CF Bronchiectasis(NCFB)
2.1.4 Diabetes
2.1.5 Other
2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017, 2022 & 2028)
2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028)
2.4 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017, 2022 & 2028)
2.5 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028)
3 Alpha 1 Antitrypsin Deficiency Treatment by End Users
3.1 Alpha 1 Antitrypsin Deficiency Treatment Market Segment by End Users
3.1.1 COPD
3.1.2 Cystic Fibrosis(CF)
3.1.3 Non-CF Bronchiectasis(NCFB)
3.1.4 Diabetes
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017, 2022 & 2028)
3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028)
3.4 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017, 2022 & 2028)
3.5 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028)
4 Global Alpha 1 Antitrypsin Deficiency Treatment Competitor Landscape by Company
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Company
4.1.1 Top Global Alpha 1 Antitrypsin Deficiency Treatment Companies Ranked by Revenue (2021)
4.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Player (2017-2022)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Concentration Ratio (CR)
4.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Alpha 1 Antitrypsin Deficiency Treatment in 2021
4.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Alpha 1 Antitrypsin Deficiency Treatment Headquarters, Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
4.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Headquarters and Area Served
4.3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Companies Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Company
4.5.1 Top Alpha 1 Antitrypsin Deficiency Treatment Players in United States, Ranked by Revenue (2021)
4.5.2 United States Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2028)
5.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017-2022
5.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.1.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.4.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Details
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.1.5 Pfizer Recent Development
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Details
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.2.5 GlaxoSmithKline Recent Development
7.3 AstraZeneca
7.3.1 AstraZeneca Company Details
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.3.5 AstraZeneca Recent Development
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Company Details
7.4.2 Boehringer Ingelheim Business Overview
7.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.4.5 Boehringer Ingelheim Recent Development
7.5 Teva Pharmaceutical Industries
7.5.1 Teva Pharmaceutical Industries Company Details
7.5.2 Teva Pharmaceutical Industries Business Overview
7.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.5.5 Teva Pharmaceutical Industries Recent Development
7.6 Takeda
7.6.1 Takeda Company Details
7.6.2 Takeda Business Overview
7.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.6.5 Takeda Recent Development
7.7 Baxter
7.7.1 Baxter Company Details
7.7.2 Baxter Business Overview
7.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.7.5 Baxter Recent Development
7.8 Grifols
7.8.1 Grifols Company Details
7.8.2 Grifols Business Overview
7.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.8.5 Grifols Recent Development
7.9 CSL Behring
7.9.1 CSL Behring Company Details
7.9.2 CSL Behring Business Overview
7.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.9.5 CSL Behring Recent Development
7.10 Kamada Ltd
7.10.1 Kamada Ltd Company Details
7.10.2 Kamada Ltd Business Overview
7.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.10.5 Kamada Ltd Recent Development
7.11 Chiesi Pharmaceuticals
7.11.1 Chiesi Pharmaceuticals Company Details
7.11.2 Chiesi Pharmaceuticals Business Overview
7.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.11.5 Chiesi Pharmaceuticals Recent Development
7.12 Kedrion Group
7.12.1 Kedrion Group Company Details
7.12.2 Kedrion Group Business Overview
7.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.12.5 Kedrion Group Recent Development
7.13 Vertex Pharmaceuticals
7.13.1 Vertex Pharmaceuticals Company Details
7.13.2 Vertex Pharmaceuticals Business Overview
7.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.13.5 Vertex Pharmaceuticals Recent Development
7.14 ProMetic Life Sciences
7.14.1 ProMetic Life Sciences Company Details
7.14.2 ProMetic Life Sciences Business Overview
7.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
7.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
7.14.5 ProMetic Life Sciences Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Figures, Tables and Charts Available in Global and United States Alpha 1 Antitrypsin Deficiency Treatment Market Report & Forecast 2022-2028
List of TablesTable 1. Alpha 1 Antitrypsin Deficiency Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Table 3. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Table 4. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
Table 5. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Table 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Alpha 1 Antitrypsin Deficiency Treatment Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Player, 2017-2022
Table 13. Global Alpha 1 Antitrypsin Deficiency Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021)
Table 15. Top Players of Alpha 1 Antitrypsin Deficiency Treatment in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Alpha 1 Antitrypsin Deficiency Treatment Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Pfizer Company Details
Table 31. Pfizer Business Overview
Table 32. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
Table 33. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 34. Pfizer Recent Development
Table 35. GlaxoSmithKline Company Details
Table 36. GlaxoSmithKline Business Overview
Table 37. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
Table 38. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 39. GlaxoSmithKline Recent Development
Table 40. AstraZeneca Company Details
Table 41. AstraZeneca Business Overview
Table 42. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
Table 43. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 44. AstraZeneca Recent Development
Table 45. Boehringer Ingelheim Company Details
Table 46. Boehringer Ingelheim Business Overview
Table 47. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
Table 48. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 49. Boehringer Ingelheim Recent Development
Table 50. Teva Pharmaceutical Industries Company Details
Table 51. Teva Pharmaceutical Industries Business Overview
Table 52. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
Table 53. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 54. Teva Pharmaceutical Industries Recent Development
Table 55. Takeda Company Details
Table 56. Takeda Business Overview
Table 57. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
Table 58. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 59. Takeda Recent Development
Table 60. Baxter Company Details
Table 61. Baxter Business Overview
Table 62. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
Table 63. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 64. Baxter Recent Development
Table 65. Grifols Company Details
Table 66. Grifols Business Overview
Table 67. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
Table 68. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 69. Grifols Recent Development
Table 70. CSL Behring Company Details
Table 71. CSL Behring Business Overview
Table 72. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
Table 73. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 74. CSL Behring Recent Development
Table 75. Kamada Ltd Company Details
Table 76. Kamada Ltd Business Overview
Table 77. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
Table 78. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 79. Kamada Ltd Recent Development
Table 80. Chiesi Pharmaceuticals Company Details
Table 81. Chiesi Pharmaceuticals Business Overview
Table 82. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
Table 83. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 84. Chiesi Pharmaceuticals Recent Development
Table 85. Kedrion Group Company Details
Table 86. Kedrion Group Business Overview
Table 87. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product
Table 88. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 89. Kedrion Group Recent Development
Table 90. Vertex Pharmaceuticals Company Details
Table 91. Vertex Pharmaceuticals Business Overview
Table 92. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
Table 93. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 94. Vertex Pharmaceuticals Recent Development
Table 95. ProMetic Life Sciences Company Details
Table 96. ProMetic Life Sciences Business Overview
Table 97. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product
Table 98. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 99. ProMetic Life Sciences Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Product Picture
Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size 2017-2028 (US$ Million)
Figure 4. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size 2017-2028 (US$ Million)
Figure 6. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share in Global 2017-2028
Figure 7. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
Figure 8. Product Picture of Augmentation Therapy
Figure 9. Product Picture of Cystic Fibrosis(CF)
Figure 10. Product Picture of Non-CF Bronchiectasis(NCFB)
Figure 11. Product Picture of Diabetes
Figure 12. Product Picture of Other
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication in 2022 & 2028
Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028) & (US$ Million)
Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
Figure 16. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication in 2022 & 2028
Figure 17. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2028) & (US$ Million)
Figure 18. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
Figure 19. Product Picture of COPD
Figure 20. Product Picture of Cystic Fibrosis(CF)
Figure 21. Product Picture of Non-CF Bronchiectasis(NCFB)
Figure 22. Product Picture of Diabetes
Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users in 2022 & 2028
Figure 24. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028) & (US$ Million)
Figure 25. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
Figure 26. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users in 2022 & 2028
Figure 27. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2028) & (US$ Million)
Figure 28. United States Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
Figure 29. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 30. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 32. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 33. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. France Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 39. China Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. India Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. China Taiwan Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Indonesia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Thailand Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Malaysia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 49. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
Figure 53. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 57. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 58. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 59. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 60. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 61. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 62. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 63. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 64. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 65. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 66. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 67. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 68. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 69. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Keyplayers in Global and United States Alpha 1 Antitrypsin Deficiency Treatment Market Report & Forecast 2022-2028
PfizerGlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences